- Home
- MRKR vs UNCY Comparison
MRKR vs UNCY Comparison
Compare MRKR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- UNCY
- Stock Information
- Founded
- MRKR N/A
- UNCY 2016
- Country
- MRKR United States
- UNCY United States
- Employees
- MRKR N/A
- UNCY N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- MRKR Health Care
- UNCY Health Care
- Exchange
- MRKR Nasdaq
- UNCY Nasdaq
- Market Cap
- MRKR 35.8M
- UNCY 31.9M
- IPO Year
- MRKR N/A
- UNCY 2021
- Fundamental
- Price
- MRKR $3.50
- UNCY $0.44
- Analyst Decision
- MRKR Strong Buy
- UNCY Strong Buy
- Analyst Count
- MRKR 1
- UNCY 4
- Target Price
- MRKR $19.00
- UNCY $5.50
- AVG Volume (30 Days)
- MRKR 34.9K
- UNCY 1.9M
- Earning Date
- MRKR 11-22-2024
- UNCY 11-13-2024
- Dividend Yield
- MRKR N/A
- UNCY N/A
- EPS Growth
- MRKR N/A
- UNCY N/A
- EPS
- MRKR N/A
- UNCY N/A
- Revenue
- MRKR $3,727,435.00
- UNCY N/A
- Revenue This Year
- MRKR $35.94
- UNCY N/A
- Revenue Next Year
- MRKR N/A
- UNCY N/A
- P/E Ratio
- MRKR N/A
- UNCY N/A
- Revenue Growth
- MRKR N/A
- UNCY N/A
- 52 Week Low
- MRKR $2.44
- UNCY $0.20
- 52 Week High
- MRKR $6.16
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- MRKR 46.47
- UNCY 51.07
- Support Level
- MRKR $3.52
- UNCY $0.44
- Resistance Level
- MRKR $3.90
- UNCY $0.55
- Average True Range (ATR)
- MRKR 0.40
- UNCY 0.06
- MACD
- MRKR -0.08
- UNCY -0.00
- Stochastic Oscillator
- MRKR 0.00
- UNCY 37.19
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.